SCHEMBL13627876

SCHEMBL13627876

O=C1/C(=N\O)c2ccccc2N1Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 2/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
GALR3 O60755 2/20 0.53
CHRM5 P08912 1/20 0.52
ATM Q13315 1/20 0.50
CA12 O43570 1/20 0.50
PRKAG1 P54619 1/20 0.50
PRKAA1 Q13131 1/20 0.50
PRKAB1 Q9Y478 1/20 0.50
MAPT P10636 3/20 0.48
LRRK2 Q5S007 1/20 0.47
ALDH1A1 P00352 1/20 0.47
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HTR4 Q13639 1/20 0.46
HTR6 P50406 1/20 0.46
BRD4 O60885 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627890 0.86 CA1 (0.53) CA9CA1CA2CHRM5ATM
SCHEMBL13627872 0.86 HSP90AA1 (0.56) CA9CA1CA2ATMCA12
SCHEMBL13627897 0.84 UBE2N (0.63) CA9CA1CA2ATMCA12
SCHEMBL4597340 0.84 CHRM5 (0.73) CA9CA1CA2CHRM5ATM
SCHEMBL13627885 0.83 ALDH1A1 (0.54) CA9CA2CA12PRKAG1PRKAB1
SCHEMBL7611051 0.82 ALDH1A1 (0.66) CA9CA1CA2CHRM5CA12
SCHEMBL7611054 0.82 ALDH1A1 (0.66) CA9CA1CA2CHRM5CA12
SCHEMBL13627896 0.81 ALDH1A1 (0.53) CA9CA1CA2CA12PRKAG1
SCHEMBL18669003 0.79 CA9 (0.61) CA9CA1CA2CHRM5ATM
SCHEMBL13627959 0.79 ALDH1A1 (0.50) CA9CA1CA2CHRM5CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CA9 4713/4885CA1 3628/4885CA2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.